Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Outcome Definition Influences the Relationship Between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients.

Zazuli Z, Otten LS, Drögemöller BI, Medeiros M, Monzon JG, Wright GEB, Kollmannsberger CK, Bedard PL, Chen Z, Gelmon KA, McGoldrick N, Kitchlu A, Vijverberg SJH, Masereeuw R, Ross CJD, Liu G, Carleton BC, Maitland-van der Zee AH.

Genes (Basel). 2019 May 10;10(5). pii: E364. doi: 10.3390/genes10050364.

2.

Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings, and Future Avenues of Research.

Drögemöller BI, Wright GEB, Lo C, Le T, Brooks B, Bhavsar AP, Rassekh SR, Ross CJD, Carleton BC.

Clin Pharmacol Ther. 2019 Apr 23. doi: 10.1002/cpt.1483. [Epub ahead of print] Review.

PMID:
31012503
3.

Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study.

Clemens E, Meijer AJ, Broer L, Langer T, van der Kooi AL, Uitterlinden AG, de Vries A, Kuehni CE, Garrè ML, Kepak T, Kruseova J, Winther JF, Kremer LC, van Dulmen-den Broeder E, Tissing WJ, Rechnitzer C, Kenborg L, Hasle H, Grabow D, Parfitt R, Binder H, Carleton BC, Byrne J, Kaatsch P, Am Zehnhoff-Dinnesen A, Zolk O, van den Heuvel-Eibrink MM.

JMIR Res Protoc. 2019 Mar 19;8(3):e11868. doi: 10.2196/11868.

4.

Analyses of Adverse Drug Reactions-Nationwide Active Surveillance Network: Canadian Pharmacogenomics Network for Drug Safety Database.

Tanoshima R, Khan A, Biala AK, Trueman JN, Drögemöller BI, Wright GEB, Hasbullah JS, Groeneweg GSS, Ross CJD, Carleton BC; Canadian Pharmacogenomics Network for Drug Safety Consortium.

J Clin Pharmacol. 2019 Mar;59(3):356-363. doi: 10.1002/jcph.1336. Epub 2018 Nov 19.

PMID:
30452777
5.

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.

Drögemöller BI, Wright GEB, Shih J, Monzon JG, Gelmon KA, Ross CJD, Amstutz U, Carleton BC; CPNDS Clinical Recommendations Group.

Breast Cancer Res Treat. 2019 Feb;173(3):521-532. doi: 10.1007/s10549-018-5027-0. Epub 2018 Nov 8.

PMID:
30411242
6.

The incidence of symptomatic osteonecrosis after allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia - controversy on dexamethasone as a risk factor.

Tanoshima R, Carleton BC.

Br J Haematol. 2019 Jun;185(5):958-959. doi: 10.1111/bjh.15657. Epub 2018 Nov 8. No abstract available.

PMID:
30408145
7.

Tumor necrosis factor inhibitors and risk of peripheral neuropathy in patients with rheumatic diseases.

Etminan M, Sodhi M, Samii A, Carleton BC, Kezouh A, Antonio Avina-Zubieta J.

Semin Arthritis Rheum. 2019 Jun;48(6):1083-1086. doi: 10.1016/j.semarthrit.2018.09.006. Epub 2018 Sep 27.

PMID:
30337056
8.

Reducing anthracycline-induced cardiotoxicity through pharmacogenetics.

Scott E, Hasbullah JS, Ross CJ, Carleton BC.

Pharmacogenomics. 2018 Oct;19(15):1147-1150. doi: 10.2217/pgs-2018-0124. Epub 2018 Sep 14. No abstract available.

9.

Antipsychotic-Associated Symptoms of Tourette Syndrome: A Systematic Review.

Kim DD, Barr AM, Chung Y, Yuen JWY, Etminan M, Carleton BC, White RF, Honer WG, Procyshyn RM.

CNS Drugs. 2018 Oct;32(10):917-938. doi: 10.1007/s40263-018-0559-8. Review.

PMID:
30121819
10.

Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis.

Kowalec K, Wright GEB, Drögemöller BI, Aminkeng F, Bhavsar AP, Kingwell E, Yoshida EM, Traboulsee A, Marrie RA, Kremenchutzky M, Campbell TL, Duquette P, Chalasani N, Wadelius M, Hallberg P, Xia Z, De Jager PL, Denny JC, Davis MF, Ross CJD, Tremlett H, Carleton BC.

Nat Genet. 2018 Aug;50(8):1081-1085. doi: 10.1038/s41588-018-0168-y. Epub 2018 Jul 16.

11.

Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes.

Wright GEB, Amstutz U, Drögemöller BI, Shih J, Rassekh SR, Hayden MR, Carleton BC, Ross CJD; Canadian Pharmacogenomics Network for Drug Safety Consortium.

Clin Pharmacol Ther. 2019 Feb;105(2):402-410. doi: 10.1002/cpt.1179. Epub 2018 Aug 17.

12.

HUME: large-scale detection of causal genetic factors of adverse drug reactions.

Mansouri M, Yuan B, Ross CJD, Carleton BC, Ester M.

Bioinformatics. 2018 Dec 15;34(24):4274-4283. doi: 10.1093/bioinformatics/bty475.

PMID:
29931042
13.

Association of Antidepressant Use With Drug-Related Extrapyramidal Symptoms: A Pharmacoepidemiological Study.

Guo MY, Etminan M, Procyshyn RM, Kim DD, Samii A, Kezouh A, Carleton BC.

J Clin Psychopharmacol. 2018 Aug;38(4):349-356. doi: 10.1097/JCP.0000000000000911.

PMID:
29901567
14.

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.

Phillips EJ, Sukasem C, Whirl-Carrillo M, Müller DJ, Dunnenberger HM, Chantratita W, Goldspiel B, Chen YT, Carleton BC, George AL Jr, Mushiroda T, Klein T, Gammal RS, Pirmohamed M.

Clin Pharmacol Ther. 2018 Apr;103(4):574-581. doi: 10.1002/cpt.1004. Epub 2018 Feb 2.

15.

Dentists’ Prescribing of Analgesics for Children in British Columbia, Canada

Etminan M, Nouri MR, Sodhi M, Carleton BC.

J Can Dent Assoc. 2017 Aug;83:h5.

16.

Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients.

Drögemöller BI, Brooks B, Critchley C, Monzon JG, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Hayden MR, Gelmon KA, Carleton BC, Ross CJD.

Clin Cancer Res. 2018 Apr 15;24(8):1866-1871. doi: 10.1158/1078-0432.CCR-17-2810. Epub 2018 Jan 22.

17.

Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients.

McCormack M, Gui H, Ingason A, Speed D, Wright GEB, Zhang EJ, Secolin R, Yasuda C, Kwok M, Wolking S, Becker F, Rau S, Avbersek A, Heggeli K, Leu C, Depondt C, Sills GJ, Marson AG, Auce P, Brodie MJ, Francis B, Johnson MR, Koeleman BPC, Striano P, Coppola A, Zara F, Kunz WS, Sander JW, Lerche H, Klein KM, Weckhuysen S, Krenn M, Gudmundsson LJ, Stefánsson K, Krause R, Shear N, Ross CJD, Delanty N; EPIGEN Consortium;, Pirmohamed M, Carleton BC; Canadian Pharmacogenomics Network for Drug Safety;, Cendes F, Lopes-Cendes I, Liao WP, O'Brien TJ, Sisodiya SM; EpiPGX Consortium;, Cherny S, Kwan P, Baum L; International League Against Epilepsy Consortium on Complex Epilepsies;, Cavalleri GL.

Neurology. 2018 Jan 23;90(4):e332-e341. doi: 10.1212/WNL.0000000000004853. Epub 2017 Dec 29. Erratum in: Neurology. 2018 Oct 16;91(16):765.

18.

Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy.

McLaughlin MJ, He Y, Brunstrom-Hernandez J, Thio LL, Carleton BC, Ross CJD, Gaedigk A, Lewandowski A, Dai H, Jusko WJ, Leeder JS.

PM R. 2018 Mar;10(3):235-243. doi: 10.1016/j.pmrj.2017.08.441. Epub 2017 Sep 1.

19.

Risk of hair loss with different antidepressants: a comparative retrospective cohort study.

Etminan M, Sodhi M, Procyshyn RM, Guo M, Carleton BC.

Int Clin Psychopharmacol. 2018 Jan;33(1):44-48. doi: 10.1097/YIC.0000000000000191.

PMID:
28763345
20.

Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.

Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Hildebrand CA, Gunaretnam EP, Critchley C, Chen Z, Brunham LR, Hayden MR, Ross CJD, Gelmon KA, Carleton BC.

JAMA Oncol. 2017 Nov 1;3(11):1558-1562. doi: 10.1001/jamaoncol.2017.0502.

21.

Fluoroquinolone Use and Risk of Carpal Tunnel Syndrome: A Pharmacoepidemiologic Study.

Cheng JZ, Sodhi M, Etminan M, Carleton BC.

Clin Infect Dis. 2017 Aug 15;65(4):684-686. doi: 10.1093/cid/cix362.

PMID:
28444196
22.

Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell lines.

Bhavsar AP, Gunaretnam EP, Li Y, Hasbullah JS, Carleton BC, Ross CJ.

PLoS One. 2017 Apr 13;12(4):e0175711. doi: 10.1371/journal.pone.0175711. eCollection 2017.

23.

Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer.

Aminkeng F, Ross CJD, Rassekh SR, Rieder MJ, Bhavsar AP, Sanatani S, Bernstein D, Hayden MR, Amstutz U, Carleton BC.

Br J Clin Pharmacol. 2017 May;83(5):1143-1145. doi: 10.1111/bcp.13218. Epub 2017 Mar 19. No abstract available.

24.

Association of Repeated Intravitreous Bevacizumab Injections With Risk for Glaucoma Surgery.

Eadie BD, Etminan M, Carleton BC, Maberley DA, Mikelberg FS.

JAMA Ophthalmol. 2017 Apr 1;135(4):363-368. doi: 10.1001/jamaophthalmol.2017.0059.

25.

Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort Study.

McMahon KR, Rod Rassekh S, Schultz KR, Pinsk M, Blydt-Hansen T, Mammen C, Tsuyuki RT, Devarajan P, Cuvelier GD, Mitchell LG, Baruchel S, Palijan A, Carleton BC, Ross CJ, Zappitelli M; Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Group.

Can J Kidney Health Dis. 2017 Feb 16;4:2054358117690338. doi: 10.1177/2054358117690338. eCollection 2017.

26.

Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study.

Etminan M, Sodhi M, Samii A, Procyshyn RM, Guo M, Carleton BC.

J Clin Psychopharmacol. 2017 Feb;37(1):102-104. doi: 10.1097/JCP.0000000000000634.

PMID:
27930495
27.

Oral morphine dosing predictions based on single dose in healthy children undergoing surgery.

Dawes JM, Cooke EM, Hannam JA, Brand KA, Winton P, Jimenez-Mendez R, Aleksa K, Lauder GR, Carleton BC, Koren G, Rieder MJ, Anderson BJ, Montgomery CJ.

Paediatr Anaesth. 2017 Jan;27(1):28-36. doi: 10.1111/pan.13020. Epub 2016 Oct 25.

PMID:
27779356
28.

Risk of Extrapyramidal Adverse Events With Aripiprazole.

Etminan M, Procyshyn RM, Samii A, Carleton BC.

J Clin Psychopharmacol. 2016 Oct;36(5):472-4. doi: 10.1097/JCP.0000000000000543.

PMID:
27580493
29.

Risk of sensorineural hearing loss with macrolide antibiotics: A nested case-control study.

Etminan M, Westerberg BD, Kozak FK, Guo MY, Carleton BC.

Laryngoscope. 2017 Jan;127(1):229-232. doi: 10.1002/lary.26190. Epub 2016 Aug 6.

PMID:
27497265
30.

Asthma in British Columbia: Are we finally breathing easier? A population-based study of the burden of disease over 14 years.

Bardal S, Smith A, Luo HA, Zhang T, Groeneweg G, Jimenez Mendez R, Goldman R, Carleton BC.

J Asthma. 2017 Apr;54(3):308-317. doi: 10.1080/02770903.2016.1208223. Epub 2016 Jul 14.

PMID:
27414432
31.

Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.

Aminkeng F, Ross CJ, Rassekh SR, Hwang S, Rieder MJ, Bhavsar AP, Smith A, Sanatani S, Gelmon KA, Bernstein D, Hayden MR, Amstutz U, Carleton BC; CPNDS Clinical Practice Recommendations Group.

Br J Clin Pharmacol. 2016 Sep;82(3):683-95. doi: 10.1111/bcp.13008. Epub 2016 Jun 30. Review.

32.

Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine.

Maagdenberg H, Vijverberg SJ, Bierings MB, Carleton BC, Arets HG, de Boer A, Maitland-van der Zee AH.

Paediatr Drugs. 2016 Aug;18(4):251-60. doi: 10.1007/s40272-016-0176-2. Review.

33.

Risk of Myocardial Infarction and Stroke With Single or Repeated Doses of Intravitreal Bevacizumab in Age-Related Macular Degeneration.

Etminan M, Maberley DA, Babiuk DW, Carleton BC.

Am J Ophthalmol. 2016 Jun;166:205. doi: 10.1016/j.ajo.2016.03.026. Epub 2016 Apr 16. No abstract available.

PMID:
27093892
34.

Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers.

Lee JW, Pussegoda K, Rassekh SR, Monzon JG, Liu G, Hwang S, Bhavsar AP, Pritchard S, Ross CJ, Amstutz U, Carleton BC; CPNDS Clinical Recommendations Group.

Ther Drug Monit. 2016 Aug;38(4):423-31. doi: 10.1097/FTD.0000000000000298. Review.

35.

Risk of Myocardial Infarction and Stroke With Single or Repeated Doses of Intravitreal Bevacizumab in Age-Related Macular Degeneration.

Etminan M, Maberley DA, Babiuk DW, Carleton BC.

Am J Ophthalmol. 2016 Mar;163:53-58. doi: 10.1016/j.ajo.2015.11.030. Epub 2015 Dec 15.

PMID:
26701272
36.

A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.

Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, Brunham LR, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Amstutz U, Rieder MJ, Bernstein D, Carleton BC, Hayden MR, Ross CJ; Canadian Pharmacogenomics Network for Drug Safety Consortium.

Nat Genet. 2015 Sep;47(9):1079-84. doi: 10.1038/ng.3374. Epub 2015 Aug 3.

37.

Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children.

Visscher H, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR, Ross CJ; CPNDS consortium.

Pharmacogenomics. 2015;16(10):1065-76. doi: 10.2217/pgs.15.61. Epub 2015 Jul 31.

PMID:
26230641
38.

Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy.

Shaw K, Amstutz U, Kim RB, Lesko LJ, Turgeon J, Michaud V, Hwang S, Ito S, Ross C, Carleton BC; CPNDS Clinical Recommendation Group.

Ther Drug Monit. 2015 Aug;37(4):428-36. doi: 10.1097/FTD.0000000000000192. Review.

39.

A Compartmental Analysis for Morphine and Its Metabolites in Young Children After a Single Oral Dose.

Velez de Mendizabal N, Jimenez-Mendez R, Cooke E, Montgomery CJ, Dawes J, Rieder MJ, Aleksa K, Koren G, Jacobo-Cabral CO, Gonzalez-Ramirez R, Castañeda-Hernandez G, Carleton BC.

Clin Pharmacokinet. 2015 Oct;54(10):1083-90. doi: 10.1007/s40262-015-0256-4.

PMID:
25773480
40.

Use of pharmacogenomics in pediatric renal transplant recipients.

Medeiros M, Castañeda-Hernández G, Ross CJ, Carleton BC.

Front Genet. 2015 Feb 18;6:41. doi: 10.3389/fgene.2015.00041. eCollection 2015. Review.

41.

Genetic markers of cisplatin-induced hearing loss in children.

Carleton BC, Ross CJ, Pussegoda K, Bhavsar AP, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR.

Clin Pharmacol Ther. 2014 Sep;96(3):296-8. doi: 10.1038/clpt.2014.92.

PMID:
25141953
42.

Development of a broad-based ADME panel for use in pharmacogenomic studies.

Brown AM, Renaud Y, Ross C, Hansen M, Mongrain I, Valois D, Carleton BC, Hayden MR, Dubé MP, Tardif JC, Phillips MS.

Pharmacogenomics. 2014 Jun;15(9):1185-95. doi: 10.2217/pgs.14.81.

PMID:
25141894
43.

Pharmacogenomic diversity in Singaporean populations and Europeans.

Brunham LR, Chan SL, Li R, Aminkeng F, Liu X, Saw WY, Ong RT, Pillai EN, Carleton BC, Toh D, Tan SH, Koo SH, Lee EJ, Chia KS, Ross CJ, Hayden MR, Sung C, Teo YY.

Pharmacogenomics J. 2014 Dec;14(6):555-63. doi: 10.1038/tpj.2014.22. Epub 2014 May 27.

PMID:
24861855
44.

Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity".

Carleton BC, Ross CJ, Bhavsar AP, Lee JW, Visscher H, Rassekh SR, Hayden MR.

Clin Pharmacol Ther. 2014 Aug;96(2):158. doi: 10.1038/clpt.2014.90. Epub 2014 Apr 22. No abstract available.

PMID:
24755913
45.

Codeine-related deaths: The role of pharmacogenetics and drug interactions.

Lam J, Woodall KL, Solbeck P, Ross CJ, Carleton BC, Hayden MR, Koren G, Madadi P.

Forensic Sci Int. 2014 Jun;239:50-6. doi: 10.1016/j.forsciint.2014.03.018. Epub 2014 Mar 26.

PMID:
24747667
46.

The emerging era of pharmacogenomics: current successes, future potential, and challenges.

Lee JW, Aminkeng F, Bhavsar AP, Shaw K, Carleton BC, Hayden MR, Ross CJ.

Clin Genet. 2014 Jul;86(1):21-8. doi: 10.1111/cge.12392. Epub 2014 May 9. Review.

47.

Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.

Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamura H, Connolly MB, Ito S, Carleton BC; CPNDS clinical recommendation group.

Epilepsia. 2014 Apr;55(4):496-506. doi: 10.1111/epi.12564. Epub 2014 Mar 5. Review.

48.

VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.

Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC.

Pediatr Blood Cancer. 2014 Jun;61(6):1055-62. doi: 10.1002/pbc.24932. Epub 2014 Jan 29.

PMID:
24474498
49.

Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy.

Madadi P, Amstutz U, Rieder M, Ito S, Fung V, Hwang S, Turgeon J, Michaud V, Koren G, Carleton BC; CPNDS Clinical Recommendations Group.

J Popul Ther Clin Pharmacol. 2013;20(3):e369-96. Epub 2013 Nov 6.

PMID:
24214521
50.

Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.

Carleton BC, Ross CJ, Bhavsar AP, Amstutz U, Pussegoda K, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR.

Clin Pharmacol Ther. 2014 Mar;95(3):253. doi: 10.1038/clpt.2013.219. Epub 2013 Nov 5. No abstract available.

PMID:
24193170

Supplemental Content

Loading ...
Support Center